All In Biotech

Drug Trial Radar · NCT03519256

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

142

Actual

Start

Aug 2, 2018

Primary completion

Aug 22, 2022

Study completion Aug 24, 2022

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.

Conditions

  • Urinary Bladder Neoplasms

Interventions

  • NivolumabBiological

    Specified dose on specified days

  • BCGBiological

    Specified dose on specified days

  • BMS-986205Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  2. Number of Participants With Serious Adverse Events (SAEs)Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  3. Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study TreatmentTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  4. Number of Participants Immune-Mediated Adverse Events (IMAEs)Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  5. Number of Participants Who DiedTime frame: From first dose to 100 days post last dose of study treatment (an average of 45 weeks up to approximately 74 weeks)
  6. Number of Participants With Specific Liver Laboratory AbnormalitiesTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  7. Number of Participants With Specific Thyroid Laboratory AbnormalitiesTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  8. Number of Participants With Changes From Baseline Laboratory ValuesTime frame: From baseline to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  9. Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) StatusTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
  10. Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) StatusTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

Locations

88 sites in 15 countries. Site status is shown where the registry gives one.

  • Local Institution - 0044

    Los Angeles, California

  • Local Institution - 0081

    Riverside, California

  • Local Institution - 0087

    San Francisco, California

  • Local Institution - 0125

    Tampa, Florida

  • Local Institution - 0056

    Hapeville, Georgia

  • Local Institution - 0023

    New Lenox, Illinois

  • Wichita Urology Group

    Wichita, Kansas

  • Local Institution - 0001

    Baltimore, Maryland

  • Local Institution - 0077

    Ann Arbor, Michigan

  • Local Institution - 0032

    Minneapolis, Minnesota

  • Local Institution - 0040

    Omaha, Nebraska

  • Local Institution - 0144

    New Brunswick, New Jersey

  • Deleware Valley Urology, LLC

    Voorhees Township, New Jersey

  • Local Institution - 0051

    New York, New York

  • Local Institution - 0058

    Columbus, Ohio

  • Local Institution - 0036

    Bala-Cynwyd, Pennsylvania

  • Local Institution - 0049

    Charleston, South Carolina

  • Local Institution - 0002

    Myrtle Beach, South Carolina

  • Local Institution - 0057

    Chattanooga, Tennessee

  • Urology Clinics Of North Texas, Pa

    Dallas, Texas

  • Local Institution - 0048

    Houston, Texas

  • Local Institution - 0140

    Houston, Texas

  • Local Institution - 0047

    Lubbock, Texas

  • Urology San Antonio Research, Pa

    San Antonio, Texas

  • Local Institution - 0141

    Seattle, Washington

  • Instituto Oncologico De Cordoba

    Córdoba, Argentina

  • Local Institution - 0137

    Mendoza, Argentina

  • Local Institution - 0068

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0065

    Capital Federal, Distrito Federal, Argentina

  • Local Institution - 0089

    Ciudad Autonoma Buenos Aires, Distrito Federal, Argentina

  • Local Institution

    Viedma, Río Negro Province, Argentina

  • Local Institution - 0146

    Camperdown, New South Wales, Australia

  • Local Institution - 0148

    St Leonards, New South Wales, Australia

  • Local Institution - 0150

    Rio de Janeiro, Brazil

  • Local Institution - 0074

    São Paulo, Brazil

  • Local Institution - 0072

    Fortaleza, Ceará, Brazil

  • Local Institution - 0151

    Curitiba, Paraná, Brazil

  • Local Institution - 0073

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Itacorubi, Florianopolis, Santa Catarina, Brazil

  • Local Institution - 0078

    Jaú, São Paulo, Brazil

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.